ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL2048484
CHEMBL2048484
Compound Name CANAGLIFLOZIN
ChEMBL Synonyms JNJ-24831754-ZAE | INVOKANA | CANAGLIFLOZIN | TA-7284 | JNJ-28431754-AAA | JNJ-28431754
Max Phase 4 (Approved)
Trade Names INVOKANA
Molecular Formula C24H25FO5S

Additional synonyms for CHEMBL2048484 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES Cc1ccc(cc1Cc2ccc(s2)c3ccc(F)cc3)[C@@H]4O[C@H](CO)[C@@H](O)[C ...
Download SMILES
Standard InChI InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12- ...
Download InChI
Standard InChI Key XTNGUQKDFGDXSJ-ZXGKGEBGSA-N

Sources

  • British National Formulary
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL2048484

Molecule Features

CHEMBL2048484 compound icon
Drug Type:Natural Product-derived Rule of Five:Y First In Class:Y Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Sodium/glucose cotransporter 2 inhibitor Sodium/glucose cotransporter 2 DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Diabetes MellitusD003920EFO:0000400diabetes mellitus1ClinicalTrials
ObesityD009765EFO:0001073obesity2ClinicalTrials
Renal InsufficiencyD0514371ClinicalTrials
Diabetes Mellitus, Type 1D003922EFO:0001359type I diabetes mellitus2ClinicalTrials
Diabetes Mellitus, Type 2D003924EFO:0001360type II diabetes mellitus4ClinicalTrials
DailyMed
DailyMed
Diabetic NephropathiesD003928EFO:0000401diabetic nephropathy3ClinicalTrials

Clinical Data

ClinicalTrials.gov CANAGLIFLOZIN
The Cochrane Collaboration CANAGLIFLOZIN

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL2048484. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL3884 Sodium/glucose cotransporter 2 Homo sapiens 1.000
CHEMBL4979 Sodium/glucose cotransporter 1 Homo sapiens 1.000
CHEMBL1770047 Low affinity sodium-glucose cotransporter Homo sapiens 1.000
CHEMBL4837 Adhesin protein fimH Escherichia coli K-12 0.954
CHEMBL3961 MAP kinase p38 beta Homo sapiens 0.513

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL3884 Sodium/glucose cotransporter 2 Homo sapiens 1.000
CHEMBL4979 Sodium/glucose cotransporter 1 Homo sapiens 1.000
CHEMBL1075302 Sodium/glucose cotransporter 2 Mus musculus 1.000
CHEMBL1770047 Low affinity sodium-glucose cotransporter Homo sapiens 1.000
CHEMBL4696 Glycogen phosphorylase, muscle form Oryctolagus cuniculus 1.000
CHEMBL4837 Adhesin protein fimH Escherichia coli K-12 0.970

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
444.5 444.1407 2.97 5 90.15 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
6 4 0 5 4 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
13.34 - 2.71 2.71 3 31 0.49

Structural Alerts

There are no structural alerts for CHEMBL2048484

Compound Cross References

ATC A - ALIMENTARY TRACT AND METABOLISM
A10 - DRUGS USED IN DIABETES
A10B - BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BK - Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BK02 - canagliflozin

ChemSpider ChemSpider:XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
DailyMed canagliflozin

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL2048484



BindingDB 50386885
ChEBI 73274
DrugBank DB08907
DrugCentral 4758
FDA SRS 6S49DGR869
Guide to Pharmacology 4582
IBM Patent System E01437342B7148A21B2BED9ECC5B26BB
LINCS LSM-45965
MolPort MolPort-021-804-941
Nikkaji J2.830.773J
PubChem 24812758
PubChem: Drugs of the Future 125299338
PubChem: Thomson Pharma 49811874
Selleck canagliflozin
SureChEMBL SCHEMBL157162
ZINC ZINC000043207238

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/XTNGUQKDFGDXSJ-ZXGKGEBGSA-N spacer
spacer